SEC23B Gene Anemia dyserythropoietic type 2 Genetic Test
Are you or a loved one experiencing symptoms of anemia dyserythropoietic type 2? DNA Labs UAE offers a comprehensive genetic test to help diagnose this inherited disorder. Our SEC23B Gene Anemia dyserythropoietic type 2 Genetic Test is designed to analyze the SEC23B gene, which is associated with this disorder.
Test Components and Price
Our SEC23B Gene Anemia dyserythropoietic type 2 Genetic Test is priced at 4400.0 AED. The test requires a blood sample, extracted DNA, or one drop of blood on an FTA card.
Report Delivery and Method
Once the sample is collected, the report will be delivered within 3 to 4 weeks. We utilize NGS (Next-Generation Sequencing) technology, which allows us to analyze multiple genes simultaneously, providing accurate and comprehensive results.
Test Type and Doctor
The SEC23B Gene Anemia dyserythropoietic type 2 Genetic Test falls under the category of Metabolic Disorders. Our team of experienced General Physicians specializes in genetic testing and will oversee your test.
Test Department and Pre Test Information
Our Genetics department handles the SEC23B Gene Anemia dyserythropoietic type 2 Genetic Test. Before the test, it is important to provide the clinical history of the patient. Additionally, a Genetic Counselling session will be conducted to draw a pedigree chart of family members affected with Anemia dyserythropoietic type 2. This information helps in the accurate interpretation of the test results.
Understanding the SEC23B Gene Anemia dyserythropoietic type 2 Genetic Test
Anemia dyserythropoietic type 2 is an inherited disorder that affects the production of red blood cells in the bone marrow. This leads to a decreased number of mature red blood cells and results in anemia. Our NGS genetic testing analyzes the SEC23B gene to identify mutations or variations that may be responsible for this disorder.
By analyzing the genetic material of an individual, our NGS genetic testing provides valuable information about the presence of mutations in the SEC23B gene. This information helps in confirming a diagnosis of anemia dyserythropoietic type 2. It also enables genetic counseling and family planning, and has the potential to aid in developing personalized treatment strategies in the future.
If you suspect anemia dyserythropoietic type 2, it is important to get tested. DNA Labs UAE is here to provide accurate and reliable genetic testing services. Contact us today to schedule your SEC23B Gene Anemia dyserythropoietic type 2 Genetic Test.
Test Name | SEC23B Gene Anemia dyserythropoietic type 2 Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Metabolic Disorders |
Doctor | General Physician |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for SEC23B Gene Anemia dyserythropoietic type 2 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with Anemia dyserythropoietic type 2 |
Test Details |
The SEC23B gene is associated with an inherited disorder called anemia dyserythropoietic type 2. This disorder affects the production of red blood cells in the bone marrow, leading to a decreased number of mature red blood cells and resulting in anemia. NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that uses advanced sequencing technology to analyze multiple genes simultaneously. In the context of anemia dyserythropoietic type 2, NGS genetic testing can be used to identify mutations or variations in the SEC23B gene that may be responsible for the disorder. By analyzing the genetic material of an individual, NGS genetic testing can provide valuable information about the presence of mutations in the SEC23B gene, helping to confirm a diagnosis of anemia dyserythropoietic type 2. This information can be used for genetic counseling, family planning, and potentially for developing personalized treatment strategies in the future. |